Pediatric Bradycardia (HR _ 60 bpm)
Asymptomatic
■ Observe—Support ABCs—Admission
to PICU
Symptomatic—severe cardiopulmonary compromise (Poor perfusion, low BP, dyspnea, ALOC despite O2 and ventilation)
■ Chest
compressions: 100/min (ratio 30:2)
■ Epinephrine*:
IV or IO—0.01 mg/kg of 1:10,000 strength
(0.1
mL/kg) q 3–5 minutes. ET—0.1 mg/kg of 1:1,000 strength
(0.1
mL/kg) q 3–5 minutes.
■ Atropine*:
0.02 mg/kg (min dose 0.1 mg) may repeat one time.
Max total
dose is 1 mg.
■ Consider
cardiac pacing: Same as for adults, but use
pediatric pads, placed anterior-to-posterior, and set rate to 100 bpm.
*Note:
If bradycardia due to suspected increased vagal tone or
primary AV block, give atropine as first-line drug.
Pediatric Tachycardia-Poor Perfusion*
Narrow-Complex (0.08 sec or less)
■ 12-lead to evaluate
tachycardia if clinically practical.
■ Consider vagal maneuvers.ERG
TRAUMA
*Note: When the tachycardia is associated
with adequate perfusion, consider
pharmacological
cardioversion first, then consider electrical cardioversion.
■
Immediate
cardioversion: 0.5–1
J/kg (repeat at 2 J/kg); or
■
Adenosine: (if IV or IO established) 0.1 mg/kg
rapid IV or IO push. Max 1st dose of 6 mg. May repeat 2nd dose at 12 mg.
Wide-Complex (> 0.08 sec)
■
12-lead to evaluate
tachycardia if clinically practical.
■
Immediate
cardioversion: 0.5–1
J/kg, (repeat at 2 J/kg)
Consider one of the following antiarrhythmic medications:
■
Amiodarone: 5 mg/kg IV over 20–60 min; or
■ Procainamide: 15 mg/kg IV over 30–60
min; or
Cardiac Arrest (ABCs-CPR-O2-Monitor-Intubate-IV) V-Fib-Pulseless
VT
■ Defibrillate:
2 J/kg, CPR for 5 cycles while recharging, 4 J/kg.
■ Epinephrine:
Same dose/route as symptomatic bradycardia.
■ Defibrillate:
2 J/kg, 2–4 J/kg, 4 J/kg (pattern: drug, CPR, shock).
■ Amiodarone:
5 mg/kg IV or IO bolus; or
■ Lidocaine:
1 mg/kg IV, IO, or ET bolus; or
■ Magnesium:
25–50 mg/kg IV, or IO max 2 gm (Torsade).
Asystole—PEA
■ Epinephrine:
Same dose/route as symptomatic bradycardia.
■ Continue CPR up
to 5 cycles and then reassess rhythm.
0 comments:
Post a Comment